Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry

M. Kojanova, M. Tanczosova, D. Strosova, P. Cetkovska, J. Fialova, T. Dolezal, A. Machovcova, S. Gkalpakiotis, BIOREP Study Group

. 2022 ; 33 (5) : 2578-2586. [pub] 20220221

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc22025055

BACKGROUND: Dupilumab has been approved to treat moderate-to-severe atopic dermatitis; however, the data in a real-world setting are still limited. OBJECTIVE: To analyze the effectiveness and safety of dupilumab. METHODS: This was a real-life Czech multicenter retrospective study from patients treated with dupilumab for severe AD. RESULTS: A total of 360 patients were included. At 16 weeks, 66.6, 34.1, and 5.5% of patients achieved EASI75/90 and EASI100, respectively. Improvement continued with the time, and the proportion of patients with EASI75/90 and EASI100 increased to 89.5, 55.6, and 12.9% after one year of treatment and reached 95.8, 60.4, and 27.1% in the second year of therapy, respectively. A significant reduction was observed in the DLQI scores. The most common adverse events were infections in 5.8% of patients, followed by ocular complications in 2.5% of patients. Persistence rates were 98.2% at four months to 93.1% at month 24, and lack of effectiveness was the most common reason for discontinuation. CONCLUSION: This real-life study confirmed the effectiveness and safety of dupilumab in a real-life setting during the COVID-19 pandemic. Our study revealed a higher frequency of infections and a lower conjunctivitis frequency than other real-life studies and clinical trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025055
003      
CZ-PrNML
005      
20241105103723.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/09546634.2022.2043545 $2 doi
035    __
$a (PubMed)35170381
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kojanova, Martina $u Department of Dermatovenereology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czechia $1 https://orcid.org/0000000198909965
245    10
$a Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry / $c M. Kojanova, M. Tanczosova, D. Strosova, P. Cetkovska, J. Fialova, T. Dolezal, A. Machovcova, S. Gkalpakiotis, BIOREP Study Group
520    9_
$a BACKGROUND: Dupilumab has been approved to treat moderate-to-severe atopic dermatitis; however, the data in a real-world setting are still limited. OBJECTIVE: To analyze the effectiveness and safety of dupilumab. METHODS: This was a real-life Czech multicenter retrospective study from patients treated with dupilumab for severe AD. RESULTS: A total of 360 patients were included. At 16 weeks, 66.6, 34.1, and 5.5% of patients achieved EASI75/90 and EASI100, respectively. Improvement continued with the time, and the proportion of patients with EASI75/90 and EASI100 increased to 89.5, 55.6, and 12.9% after one year of treatment and reached 95.8, 60.4, and 27.1% in the second year of therapy, respectively. A significant reduction was observed in the DLQI scores. The most common adverse events were infections in 5.8% of patients, followed by ocular complications in 2.5% of patients. Persistence rates were 98.2% at four months to 93.1% at month 24, and lack of effectiveness was the most common reason for discontinuation. CONCLUSION: This real-life study confirmed the effectiveness and safety of dupilumab in a real-life setting during the COVID-19 pandemic. Our study revealed a higher frequency of infections and a lower conjunctivitis frequency than other real-life studies and clinical trials.
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    12
$a COVID-19 $7 D000086382
650    12
$a atopická dermatitida $x farmakoterapie $7 D003876
650    _2
$a lidé $7 D006801
650    _2
$a pandemie $7 D058873
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Česák, Milena, $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Kralovske Vinohrady University Hospital, Prague, Czechia $d 1993- $7 xx0234961
700    1_
$a Strosova, Daniela $u Value Outcomes, Prague, Czechia
700    1_
$a Cetkovska, Petra $u Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Prague, Czechia
700    1_
$a Fialova, Jorga $u Department of Dermatovenereology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czechia
700    1_
$a Dolezal, Tomas $u Value Outcomes, Prague, Czechia
700    1_
$a Machovcova, Alena $u Motol University Hospital, Prague, Czechia
700    1_
$a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Kralovske Vinohrady University Hospital, Prague, Czechia $1 https://orcid.org/0000000269565961
710    2_
$a BIOREP Study Group
773    0_
$w MED00004913 $t Journal of dermatological treatment $x 1471-1753 $g Roč. 33, č. 5 (2022), s. 2578-2586
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35170381 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20241105103719 $b ABA008
999    __
$a ok $b bmc $g 1854655 $s 1176345
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 33 $c 5 $d 2578-2586 $e 20220221 $i 1471-1753 $m Journal of dermatological treatment $n J Dermatolog Treat $x MED00004913
LZP    __
$a Pubmed-20221017
Back

Find record

Citation metrics

Archiving options